Abstract
The value of the inclusion of doxorubicin hydrochloride (dox) in Cooper type regimens in advanced breast cancer was assessed by performing an overview employing summary statistics derived from published papers of randomised clinical trials comparing Cooper type regimens that contain dox with regimens in which dox was replaced by one or more compounds. Trials were selected which published data on survival, time to treatment failure and response rate. This study suggests that dox confers advantages on all of these endpoints and that the size of such benefits needs to be taken into account when deciding whether to use dox.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
A'Hern, R., Smith, I. & Ebbs, S. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67, 801–805 (1993). https://doi.org/10.1038/bjc.1993.146
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.146
This article is cited by
-
Triple negative breast cancer: approved treatment options and their mechanisms of action
Journal of Cancer Research and Clinical Oncology (2023)
-
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
International Journal of Clinical Oncology (2021)
-
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center
Journal of the Egyptian National Cancer Institute (2020)
-
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur–gimeracil–oteracil potassium in metastatic and recurrent breast cancer
Breast Cancer (2015)
-
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy
Breast Cancer Research and Treatment (2011)